Curis Highlights Emavusertib at Upcoming Healthcare Conferences for Oncology Advancement

Curis Amplifies Focus on Emavusertib with Upcoming Conferences

Curis, Inc., a biotechnology company headquartered in Lexington, Massachusetts, is poised to enhance its visibility in the oncology sector with the upcoming participation of President and CEO James Dentzer in two key healthcare conferences. The Cantor Global Healthcare Conference, occurring from September 3–5, and the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, will serve as platforms for Curis to present its innovative research and clinical developments. Dentzer's participation includes a fireside chat on September 5 at 9:45 am ET, followed by a company presentation on September 10 at 10:00 am ET. Both sessions will be accessible via webcast on Curis's website, allowing for broader engagement with stakeholders and potential investors.

A primary focus of Curis's development efforts is emavusertib (CA-4948), an oral IRAK4 inhibitor currently advancing through clinical studies. The drug is being evaluated in the TakeAim Lymphoma Phase 1/2 study for patients suffering from relapsed or refractory primary central nervous system lymphoma (PCNSL). Additionally, it is under investigation in the TakeAim Leukemia Phase 1/2 study, targeting relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (hrMDS). Emavusertib has garnered Orphan Drug Designation from both the FDA and the European Commission for its potential in treating PCNSL, AML, and MDS, positioning Curis at the forefront of innovative cancer therapies.

Furthermore, Curis's strategic collaboration with Aurigene Discovery Technologies Limited has granted the company exclusive rights to emavusertib, amplifying its research and development capabilities. The company previously licensed its rights to Erivedge®, an advanced basal cell carcinoma treatment, to Genentech, showcasing its commitment to developing and commercializing groundbreaking therapies. As Curis prepares for these high-profile conferences, it aims to highlight its advancements in oncology research and secure potential partnerships that align with its mission to improve patient outcomes.

In addition to the presentations, Curis encourages interested parties to visit its website for detailed information on ongoing clinical trials and the therapeutic potential of emavusertib. As the company continues to progress in its clinical studies, it remains dedicated to its vision of bringing innovative treatments to patients in need.